Skin Conditions & Dermatology Clinical Trials Update: Week 26, 2026

Published June 26, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Opzelura Experience Study

This Phase 4 study is testing a topical medication called ruxolitinib for people with atopic dermatitis, a common skin condition that causes itching and redness. The goal is to simplify treatment by using just one drug, which may help patients follow their treatment plan more easily and improve their skin symptoms. The study is currently recruiting in the United States and plans to enroll 50 participants.

Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis

This recently completed Phase 3 trial tested the drug guselkumab, a type of antibody treatment, in people with moderate-to-severe plaque or scalp psoriasis who have skin of color. Psoriasis can cause thick, scaly patches on the skin that affect quality of life. If effective, guselkumab could provide a new targeted treatment option to help reduce symptoms and improve daily living for this group. The study enrolled participants in the US and Canada and results are now available.

Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants Aged 6 to 23 Months With Moderate-to Severe Atopic Dermatitis

This Phase 2 study is planned to test the safety and effectiveness of nemolizumab in very young children aged 6 to 23 months who have moderate-to-severe atopic dermatitis. Atopic dermatitis in infants can be hard to manage, and new treatments are needed when topical creams do not work well enough. If successful, this trial could lead to new options for treating young children with this condition. The study is not yet recruiting and aims to include 35 participants.

A Study to Learn How Safe ACT-777991 is and How Well it Works in Adults With Non-segmental Vitiligo

This Phase 2 trial will evaluate an oral drug called ACT-777991 in adults with non-segmental vitiligo, a condition where patches of skin lose their color. The study will assess how well the drug restores skin pigmentation and its safety over 24 weeks. If this pill proves effective, it could offer a convenient new treatment choice for people seeking to improve skin color without more invasive procedures. The study is currently not yet recruiting.

Tirbanubulin (Klisiry®) in the Treatment of Basal Cell Carcinoma

This Phase 2 trial is testing a topical ointment, Tirbanubulin, for adults with superficial basal cell carcinoma, a common form of skin cancer. This treatment could provide a simpler and less invasive alternative to surgery or other therapies by being applied directly to the skin. The study is recruiting in France and plans to enroll 50 participants.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.